Objective: This meta-analysis was performed to evaluate the effect of spinal anesthesia (SA) using bupivacaine combined with dexmedetomidine (DEX) in cesarean section, analyze the adverse drug reactions induced by this mixture, and provide a reference for rational drug use. Methods: Randomized controlled trials were obtained from the PubMed, Cochrane Library, and Embase databases. The primary outcome measure was the time to the highest sensory block level (min), and the secondary outcome measure was adverse effects. Results: The time to the highest sensory block level was significantly shorter in the bupivacaine-DEX group than in the control group (standardized mean difference, À0.23; 95% confidence interval, À0.43 to À0.03). The incidence of shivering during the process of anesthesia, especially at a dose of 5 mg DEX, was significantly lower in the bupivacaine-DEX group than in the control group (odds ratio, 0.26; 95% confidence interval, 0.14-0.49). No significant differences were observed in the symptoms of hypotension, bradycardia, nausea/vomiting, or pruritus. Conclusion: Compared with the use of bupivacaine alone for SA in cesarean section, adding dexmedetomidine during SA can significantly shorten the onset time and decrease the rate of shivering during anesthesia.
Introduction
In recent decades, marked changes have taken place in parturition. 1 The overall rate of cesarean section (C-section) is significantly increasing worldwide. [2] [3] [4] Anesthesia during C-section can eliminate pain and shows few adverse effects in the mother and infant. The ideal anesthetic technique is characterized by a short time to establishment of successful anesthesia, minimal hemodynamic changes, and few adverse effects. 5 Choosing the appropriate anesthetic and proper anesthesia method can effectively reduce injury to the mother and newborn. Spinal anesthesia (SA) 6 is the preferred method during most surgical operations, especially C-section. Because of the dense and predictable block associated with SA, this technique exhibits a quicker onset and fewer complications compared with other anesthetic protocols. However, the adverse effects of neuraxial analgesia, such as maternal hypotension, shivering, vomiting or nausea, and a faint feeling, cannot be underestimated. 7 Adjuvant drugs are required to enhance the safety of anesthesia. The optimal anesthetic and adjuvant drugs should not only maintain the appropriate anesthetic effect during the puerperal period but also have limited transportation from the mother's body to the fetus.
Dexmedetomidine (DEX) is a highly selective agonist of a2-adrenergic receptors. 8 Increasingly more anesthetists are choosing DEX as a safe and effective local adjuvant drug in SA. [9] [10] [11] [12] Studies have shown that DEX can potentially prolong the blockade duration and enhance the anesthetic action. 9, [13] [14] [15] However, it is necessary to analyze the effectiveness of DEX in C-section because of the special characteristics of this surgery. Although several meta-analyses of randomized controlled trials (RCTs) have indicated that DEX is a potential anesthetic adjuvant that can facilitate better anesthetic effects in local anesthesia, 12, 16 little research has been focused on the use of DEX in C-section. Whether the addition of DEX is beneficial remains unknown because of the lack of hard evidence. Based on previously published studies, the present meta-analysis was performed to determine the effect of bupivacaine combined with DEX for SA in C-section, analyze the adverse drug reactions induced by this combination of drugs, and provide a reference for rational drug use.
Materials and methods

Search strategy
Relevant studies published in the PubMed (1996-2017), Cochrane Library (1989-2017), and Embase (1980-2017) databases were searched in October 2017 for RCTs involving bupivacaine alone and bupivacaine-DEX in C-section using SA. The following search terms were used: bupivacaine, dexmedetomidine, DEX, and cesarean section. No language restrictions were imposed. Manual searches were also conducted by reviewing the references of all publications. The included studies were published in peer-reviewed journals as full articles; none were published in gray literature or conference proceedings.
Inclusion and exclusion criteria
The retrieved articles were selected according to the following preset inclusion and exclusion criteria. Inclusion criteria The title, abstract, and full text of each RCT were scanned. The retrieved studies were independently selected by two investigators. Disagreements were resolved by a discussion with a third independent investigator.
Quality assessment and data extraction
Two reviewers independently evaluated the risk of bias of the included RCTs according to the RCT bias risk assessment tools of the Cochrane Handbook Version 5.1.
Characteristics including study information, study design, sample information, surgical information, and sample size calculation were extracted from each study. The anesthesia outcomes were also obtained directly from the recruited articles. The time to achievement of the highest sensory block level (min) and the duration of the sensory block, which might be the main difference between groups, was abstracted as the primary outcome measure. The secondary outcome was the incidence of adverse effects, including hypotension, bradycardia, nausea or vomiting, shivering, and pruritus. Two researchers independently performed the data extraction and settled any disagreements by discussion with a third researcher.
Meta-analysis
The primary and secondary outcomes were analyzed in this study. As a continuous variable, the time to the highest sensory block level was analyzed by combining the standardized mean difference (SMD) and 95% confidence interval (CI). An SMD of >1 and p value of <0.05 suggested that more time was required for anesthesia in the case group than in the control group. For dichotomous outcomes (adverse reactions to anesthesia), the odds ratio (OR) and 95% CI were used as effect indicators. A primary outcome with an OR of >1 and p value of <0.05 indicated that the anesthesia effect was better than that in the control group.
Cochran's Q test and the I 2 test 17 were used to determine the heterogeneity among the included articles. A p value of <0.05 in Cochran's Q test or an I 2 value 17 of >50% indicated significant heterogeneity, and the data were analyzed using a random-effects model. Otherwise, a fixed-effects model was chosen. All statistical analyses were performed using STATA 12.0 software (StataCorp, College Station, TX, USA).
Sensitivity analysis
To evaluate the sensitivity, each study was removed one by one during the metaanalysis. The combined effect values were then compared. Reversal of a combined result after removing a study indicated an unstable analysis result. The sensitivity analysis was also performed using STATA 12.0 software (StataCorp).
Ethics
Ethics approval was unnecessary for this meta-analysis.
Results
Literature research
As shown in Figure 1 , articles were identified using index words from the PubMed, Embase, and Cochrane Library databases. Twenty-one duplicate articles were then eliminated. According to the inclusion and exclusion criteria, seven reviews, one case report, and one study involving only intravenous DEX were eliminated after reading the titles and abstracts. For studies of post C-section intravenous analgesia, one article with duplicate data, and two studies using combined spinal-epidural anesthesia were excluded after reading the full text. Finally, six studies 14, [18] [19] [20] [21] [22] were included in this meta-analysis. 
Characteristics of the included studies
All six studies were well-designed RCTs, and the type of anesthesia was SA. The general data of each study, such as the sample inclusion/exclusion criteria, anesthetic medications, and number of patients in each group, are shown in Table 1 . In total, 494 C-sections and 3 DEX doses were included.
Risk of bias assessment
The quality of the included studies according to the Cochrane Handbook for Systematic Review of Interventions is shown in Figure 2 . All six studies showed low bias except for one RCT, in which the randomization was unclear.
Analysis
Primary outcomes. We combined the time to achievement of the highest sensory block level (min). According to the heterogeneity result, a random-effects model was used in our meta-analysis because the heterogeneity was not statistically significant (I 2 < 50%). A noticeable difference was present between the case and control groups as shown in Figure 3 (a), and a random-effects model was chosen (I 2 ¼ 0.0%). The time to achieve the highest sensory block level was significantly shorter in the bupivacaine-DEX group than in the control group (SMD, À0.23; 95% CI, À0.43 to À0.03; p ¼ 0.026). However, no significant differences were found when bupivacaine was combined with different doses of DEX in SA compared with bupivacaine alone: lowest dose of DEX (2.5 or 3 mg): I 2 ¼ 0.0%; SMD, À0.220; 95% CI, À0.61 to 0.17; moderate dose of DEX (5 mg): I 2 ¼ 0.0%; SMD, À0.22; 95% CI, À0.51 to 0.08; and high dose of DEX (10 mg): I 2 ¼ 0.0%; SMD, À0.26; 95% CI, À0.65 to 0.13. No publication bias was found according to the results of Egger's and Begg's tests (Figure 3(b) ). The significance of the pooled SMD was strongly influenced by omitting any single study in the sensitivity analysis. After eliminating the studies by He et al. 19 and Sun et al., 18 the result showed that bupivacaine-DEX could not shorten the time to achievement of the highest sensory block level (Figure 3(c) ). Moreover, the duration of the sensory block was analyzed. No significant difference was found between the bupivacaine-DEX group and control group. DEX could not prolong the duration of the sensory block (I 2 ¼ 0.0%; SMD, 1.62; 95% CI, 1.28-1.95) (Figure 4 ).
Secondary outcomes.
As the secondary outcome, we analyzed the adverse effects of anesthesia between the case and control groups. The pooled results shown in Figure 5 indicate that the incidence of shivering during the process of anesthesia was significantly lower in the case than control group (OR, 0.389; 95% CI, 0.240-0.632; p < 0.001). Figure 5 shows grouping by dose, and bupivacaine combined with 5 mg of DEX in SA was associated with a lower incidence of shivering (OR, 0.259; 95% CI, 0.136-0.491; p < 0.001). No significance differences were found in the other subgroups.
With respect to other adverse effects, no differences were observed in the symptoms of hypotension (OR, 1.197; 95% CI, 0.607-2.358) (Figure 6(a) ), bradycardia (OR, 1.423; 95% CI, 0.440-4.607) (Figure 6(b) ), nausea/vomiting (OR, 1.246; 95% CI, 0.649-2.391) (Figure 7  (a) ), or pruritus (OR, 0.894; 95% CI, 0.354-2.260) (Figure 7(b) ).
No publication bias was found according to the results of Egger's and Begg's tests for the pooled incidence rate of adverse effects. The significance of the pooled ORs was not strongly influenced by omitting any single study in the sensitivity analysis. The low sensitivity of the included data in this study indicated good stability of our meta-analysis. 
Discussion
This meta-analysis of six RCTs was performed to evaluate the efficacy and safety of bupivacaine combined with DEX in SA among patients undergoing C-section. The main result showed that bupivacaine combined with DEX in SA could improve the characteristics of the anesthetic block by shortening the time to achievement of the highest sensory block level. In addition, we found that the incidence of shivering was lower with bupivacaine-DEX than bupivacaine alone. Bupivacaine and 5 mg of DEX appeared to have the lowest shivering incidence rate among all groups.
DEX, an a2-adrenergic receptor agonist, has been approved by the Food and Drug Administration for short-term sedation and analgesia in the intensive care unit. Different from other sedative-hypnotic drugs, sedation caused by DEX may lead to natural non-rapid eye movement sleep, 25 and patients can be roused and cooperate well during the operation. The use of DEX can also notably reduce the dose of combined anesthetics. 26 Studies have shown that DEX plays a role in the regulation of blood pressure, [27] [28] [29] breathing, 30, 31 and production of hormones, 32 resulting in its extensive application in the clinical setting, especially in anesthesia. Kanazi et al. 13 compared the onset and duration of sensory and motor block caused by bupivacaine alone or bupivacaine combined with DEX. The results showed that DEX could significantly enhance the anesthetic effect of local anesthesia. A randomized double-blind study by Fares et al. 33 showed that DEX together with bupivacaine can increase the duration of anesthesia and improve hemodynamic stability. Kathuria et al. 34 concluded that DEX as an adjuvant to ropivacaine could shorten the sensory and motor block onset time and prolong the duration of anesthesia. Al-Mustafa et al. 35 indicated that the onset time of bupivacaine together with DEX was shorter than that in the control group, the duration of anesthesia was longer, and the dose was lower.
Although DEX works well regardless of whether it is used in general anesthesia or local anesthesia, it is seldom used in C-section because little evidence of safety is available. Some studies have indicated that DEX shows no harm to either the mother or fetus. During general anesthesia in patients undergoing C-section, no difference was found in the maternal arterial blood gas parameters, fetal umbilical blood gas parameters, or neonate Apgar score between the DEX and no-DEX groups. 36 In another study, the addition of DEX during local anesthesia in patients undergoing C-section reduced the dose of opioid analgesics with no influence on the neonate Apgar score. 37, 38 Furthermore, some studies have revealed a faster onset time of DEX used in anesthesia. Kim et al. 39 considered that adding DEX to bupivacaine resulted in faster onset when compared with bupivacaine alone among patients of advanced age undergoing transurethral prostatectomy. The same results were found in other studies involving anesthesia for lower limb procedures and transurethral resection of prostate or bladder tumors under SA. 13, 40 Our study showed identical results in patients undergoing C-section; namely, that bupivacaine combined with DEX can reduce the onset time to achievement of the highest sensory block level.
As a common complication of SA, shivering is observed at a higher rate among patients undergoing C-section and causes discomfort and dissatisfaction in the parturient. The shivering in patients undergoing C-section might be induced by the high metabolic rate in the late third trimester of pregnancy, accelerated blood circulation, and loss of heat accompanied by childbirth. The vascular compensatory contraction in the unblocked area induced by low blood pressure after anesthesia may increase the incidence of shivering. Consistent with our study, Mason and Lerman 41 observed anti-shivering effects in the DEX group of their study. The decrease in the shivering rate might be related to the function of DEX, 42, 43 which can inhibit the heatregulating center through activation of a2-adrenergic receptors, decrease the temperature threshold of shivering, 44 and suppress the afferent temperature information at the spinal level. Moreover, we found that 5 mg of DEX might show more advanced effects than other doses in the present study, although fewer studies were included in the subgroup analysis. No significant difference was found between the 3-and 10-mg doses, which is consistent with the findings by Zhang et al. 45 showing that 10 mg of DEX in SA failed to show superiority over 5 mg of DEX in the prevention of perioperative shivering.
The results of our study and the evidence provided by other studies indicate that DEX combined with bupivacaine can be a good choice in SA during C-section. However, the present meta-analysis still has several limitations. First, the literature research was performed using three main databases (PubMed, Embase, and the Cochrane Library), and the language of the articles was restricted to English or Chinese only. Therefore, we cannot assume that we captured all relevant information. Second, because of the small number of analyses and various doses of DEX in the included studies, dose-related conclusions are difficult to make. Additionally, long-term effects, adverse effects, neonatal outcomes, and Apgar scores at least up to 15 minutes after using DEX in SA during C-section were not analyzed because of the lack of relevant research. Finally, because of the limited information acquired from the included articles, we could only analyze the impact on the mother's body; no effects on the fetus were evaluated. Thus, more studies are needed, and a particular subgroup analysis should be done in the future.
In conclusion, compared with the use of bupivacaine alone for SA in C-section, adding DEX during SA can significantly shorten the onset time and decrease the rate of shivering during anesthesia. DEX is an effective adjuvant drug in C-section.
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